On December 4, the US Food and Drug Administration (FDA) approved durvalumab for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
For more information, read the FDA announcement or the AstraZeneca press release.
Posted on 12/6/2024
The 2026 NCCN Fall Policy Summit explored the current state of cancer screening and prevention services in the US, barriers that still drive disparities in screening uptake, and strategies to shift the paradigm of preventive cancer care.
